Furthermore, preclinical models of iCCA exhibiting activation of the MAPK pathway in the absence of K-Ras mutations should be established and subjected to MEK inhibitors in order to evaluate their relevance in vivo. This evidence concerns the gene KRAS and infantile convulsions and choreoathetosis.